Stock listing
ASX:IVX Invion Ltd. Share Price
Home listing (ASX) of Invion Ltd.
Follow Invion Ltd. into a list and get an email when it puts out news.
Share price · ASX:IVX
$0.034 AUD 0.000 (0.0%)
Close on Nov 19, 2026
- Day range
- $0.034 – $0.034 AUDNov 19, 2026
- Volume
- 36 sharesNov 19, 2026
- Market cap
- $3.76M AUDAt the close on Nov 19, 2026 · price × 110.6M shares outstanding
- 52-week range
- $0.032 – $0.110 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $3,462 AUDMedian day 28,893 shares · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:IVX · Home | $0.034 AUD | 0.000 (0.0%) | 36 | $0.034 | $0.034 | $0.034 | $0.034 | Close on Nov 19, 2026 |
| Frankfurt:7C8 | €0.021 EUR | 0.000 (0.0%) | — | €0.021 | €0.021 | €0.021 | €0.021 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:IVX · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.034 | 0.000 | 0.0% | $0.034 | $0.034 | $0.034 | 36 | |
| $0.034 | 0.000 | 0.0% | $0.033 | $0.034 | $0.033 | 26,383 | |
| $0.034 | -0.003 | -8.1% | $0.034 | $0.034 | $0.034 | 5,000 | |
| $0.037 | +0.004 | +12.1% | $0.037 | $0.037 | $0.037 | 15,005 | |
| $0.033 | -0.004 | -10.8% | $0.034 | $0.034 | $0.033 | 183,503 | |
| $0.037 | +0.003 | +8.8% | $0.037 | $0.037 | $0.037 | 92 | |
| $0.034 | -0.003 | -8.1% | $0.037 | $0.037 | $0.034 | 17,165 | |
| $0.037 | +0.003 | +8.8% | $0.037 | $0.037 | $0.037 | 10,094 | |
| $0.034 | -0.003 | -8.1% | $0.034 | $0.035 | $0.034 | 4,775 | |
| $0.037 | 0.000 | 0.0% | $0.036 | $0.037 | $0.036 | 13,000 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 718 | |
| $0.037 | +0.004 | +12.1% | $0.036 | $0.037 | $0.036 | 149,330 | |
| $0.033 | +0.001 | +3.1% | $0.033 | $0.033 | $0.033 | 157,500 | |
| $0.032 | -0.004 | -11.1% | $0.037 | $0.040 | $0.032 | 387,993 | |
| $0.036 | -0.002 | -5.3% | $0.038 | $0.038 | $0.036 | 305,623 | |
| $0.038 | +0.004 | +11.8% | $0.035 | $0.038 | $0.035 | 161,342 | |
| $0.034 | -0.001 | -2.9% | $0.035 | $0.035 | $0.034 | 27,010 | |
| $0.035 | 0.000 | 0.0% | $0.034 | $0.035 | $0.034 | 2,690 | |
| $0.035 | -0.002 | -5.4% | $0.037 | $0.037 | $0.035 | 28,423 | |
| $0.037 | +0.003 | +8.8% | $0.037 | $0.039 | $0.035 | 202,556 | |
| $0.034 | -0.004 | -10.5% | $0.037 | $0.037 | $0.034 | 204,823 | |
| $0.038 | -0.002 | -5.0% | $0.042 | $0.042 | $0.038 | 2,877 | |
| $0.040 | -0.002 | -4.8% | $0.040 | $0.040 | $0.040 | 17,500 | |
| $0.042 | +0.004 | +10.5% | $0.038 | $0.042 | $0.038 | 176,435 | |
| $0.038 | 0.000 | 0.0% | $0.038 | $0.038 | $0.038 | 71 | |
| $0.038 | +0.001 | +2.7% | $0.038 | $0.038 | $0.038 | 71 | |
| $0.037 | -0.001 | -2.6% | $0.038 | $0.038 | $0.037 | 519,900 | |
| $0.038 | 0.000 | 0.0% | $0.039 | $0.039 | $0.038 | 50,000 | |
| $0.038 | 0.000 | 0.0% | $0.038 | $0.038 | $0.038 | 29,362 | |
| $0.038 | -0.001 | -2.6% | $0.040 | $0.040 | $0.038 | 123,956 | |
| $0.039 | -0.006 | -13.3% | $0.044 | $0.044 | $0.039 | 34,351 | |
| $0.045 | 0.000 | 0.0% | $0.045 | $0.045 | $0.045 | 2,371 | |
| $0.045 | 0.000 | 0.0% | $0.045 | $0.045 | $0.045 | 4 | |
| $0.045 | +0.002 | +4.7% | $0.044 | $0.045 | $0.044 | 88,117 | |
| $0.043 | +0.005 | +13.2% | $0.040 | $0.043 | $0.040 | 125,000 | |
| $0.038 | -0.002 | -5.0% | $0.038 | $0.038 | $0.038 | 4,929 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.038 | 52,829 | |
| $0.040 | +0.004 | +11.1% | $0.039 | $0.040 | $0.039 | 178,929 | |
| $0.036 | 0.000 | 0.0% | $0.036 | $0.038 | $0.036 | 160,400 | |
| $0.036 | -0.001 | -2.7% | $0.039 | $0.039 | $0.036 | 39,612 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 11,000 | |
| $0.037 | +0.001 | +2.8% | $0.037 | $0.037 | $0.037 | 5,000 | |
| $0.036 | -0.002 | -5.3% | $0.036 | $0.036 | $0.036 | 1,059 | |
| $0.038 | -0.001 | -2.6% | $0.037 | $0.039 | $0.036 | 320,735 | |
| $0.039 | +0.002 | +5.4% | $0.037 | $0.039 | $0.036 | 167,604 | |
| $0.037 | -0.001 | -2.6% | $0.039 | $0.039 | $0.037 | 33,160 | |
| $0.038 | +0.001 | +2.7% | $0.038 | $0.038 | $0.038 | 10,000 | |
| $0.037 | 0.000 | 0.0% | $0.041 | $0.041 | $0.037 | 447,485 |
Splits
3 splits since 2011 · ASX:IVX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-100 | Consolidation | |
| 1.2663-for-1 | Split | |
| 1.028-for-1 | Split |
- Ticker
- ASX:IVX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 18, 2026
Invion Receives $0.5m R&D Tax Incentive Rebate
Latest deck · Apr 22, 2026
BIONNOVA 2026
Conference · 17 slides
Latest news
Invion Receives $0.5m R&D Tax Incentive Rebate
Nov 18, 2026
Closed $0.034 (0.0%) on Nov 19, 2026
Change of Director's Interest Notice - Thian Chew
Nov 17, 2026
Closed $0.034 (0.0%) on Nov 18, 2026
Notification of cessation of securities - IVX
Nov 17, 2026
Closed $0.034 (0.0%) on Nov 18, 2026
IVX Director Appointment/Resignation & New Company Secretary
Nov 10, 2026
Closed $0.033 (-10.8%) on Nov 11, 2026
Appendix 4C and Quarterly Activities Report - September 2026
Oct 28, 2026
Closed $0.034 (-8.1%) on Oct 30, 2026
Notice of Annual General Meeting/Proxy Form
Oct 23, 2026
Closed $0.037 (+12.1%) on Oct 23, 2026
Proposed issue of securities - IVX
Oct 20, 2026
Closed $0.032 (-11.1%) on Oct 21, 2026
Funding Agreements Cover Up to 85% of Clinical Trials Costs
Oct 20, 2026
Closed $0.032 (-11.1%) on Oct 21, 2026
Photosoft & Novel Immunotherapy Collab Partnership
Oct 19, 2026
Closed $0.036 (-5.3%) on Oct 20, 2026
PER: Percheron and Invion Explore Cancer Combination Therapy
Oct 19, 2026
Closed $0.036 (-5.3%) on Oct 20, 2026
Invion Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 133 in all · newest Nov 18, 2026 · oldest 2016
- Decks
- 45 decks · latest Apr 22, 2026
Where Invion Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:IVX · Home listing · This page | ASX | Australia | AUD |
| Frankfurt:7C8 | Frankfurt | Germany | EUR |
| OTC:IVIXF | OTC | United States | USD |
Valuation
EV/sales 12.2× against a median of 28.0×: 2nd lowest of 4 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- $4.71M AUD
- P/E
- Loss
- EV/sales
- 12.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- 100.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Invion Ltd. · ASX:IVX | US$2.49M | US$3.12M | n/a | 12.2× | n/a | 0.7× | n/a | 0.3× | n/a |
| Bioxytran, Inc. · OTC:BIXT | US$2.66M | US$2.59M | n/a | n/a | n/a | n/a | n/a | n/a | -1.20 |
| BioAtla, Inc. · NASDAQ:BCAB | US$2.58M | US$2.01M | n/a | n/a | n/a | n/a | n/a | n/a | -0.34 |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Median of the others | US$2.41M | US$2.10M | 0.7× | 28.0× | 0.3× | −63.4% | 0.0× | 1.10 |
Team and board
Officers
| Officer | Role |
|---|---|
| Thian Chew | Executive Chair and CEO |
| Melanie Leydin | Non-Executive Director, Company Secretary & CFO |
| Louise White | Executive Manager |
Board
| Director | Role |
|---|---|
| Robert Ramsay | Chair of the Board |
| Thian Chew | Executive Chair and CEO |
| Alan Yamashita | Non-Executive Director |
| Melanie Leydin | Non-Executive Director, Company Secretary & CFO |
| Paul Field | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 29, 2025 | +3.9% |
| Q2 2025 | Feb 28, 2025 | −3.6% |
| Q2 2023 | Feb 23, 2023 · After close | −6.7% |
| Q4 2022 | Aug 17, 2022 · After close | 0.0% |
| Q2 2022 | Feb 22, 2022 | 0.0% |
| Q4 2021 | Aug 4, 2021 | 0.0% |
| Q2 2021 | Feb 25, 2021 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| BIONNOVA 2026 | Conference | 17 slides | Apr 22, 2026 |
| EMERGENCE 2026 Investment Conference | Conference | 15 slides | Feb 19, 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 15 slides | Nov 26, 2025 |
| Investor Presentation (June 2025) | Investor deck | 29 slides | Jun 4, 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 20 slides | Nov 14, 2024 |
| Investor Presentation (September 2024) | Investor deck | 25 slides | Sep 19, 2024 |
| BioCentury-BayHelix East-West Summit 2024 | Conference | 29 slides | Mar 5, 2024 |
| Shareholder Meeting (November 2023) | Shareholder meeting | 19 slides | Nov 29, 2023 |
| Investor Presentation (October 2023) | Investor deck | 18 slides | Oct 24, 2023 |
| Shareholder Meeting (April 2023) | Shareholder meeting | 12 slides | Apr 6, 2023 |
All 45 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2022) | Shareholder meeting | 18 slides | Nov 17, 2022 |
| AusBioInvest 2022 | Conference | 23 slides | Oct 27, 2022 |
| 11th Annual Australian Microcap Investment Conference (October 2022) | Conference | 21 slides | Oct 18, 2022 |
| Investor Presentation (June 2022) | Investor deck | 20 slides | Jun 27, 2022 |
| Investor Presentation (February 2022) | Investor deck | 13 slides | Feb 3, 2022 |
| Shareholder Meeting (November 2021) | Shareholder meeting | 8 slides | Nov 9, 2021 |
| Shareholder Meeting (October 2020) | Shareholder meeting | 13 slides | Oct 21, 2020 |
| Shareholder Meeting (November 2019) | Shareholder meeting | 32 slides | Nov 4, 2019 |
| Corporate Update (February 2019) | Corporate update | 35 slides | Feb 28, 2019 |
| Shareholder Meeting (November 2018) | Shareholder meeting | 15 slides | Nov 13, 2018 |
| Investor Presentation (February 2018) | Investor deck | 37 slides | Feb 12, 2018 |
| Investor Presentation (December 2017) | Investor deck | 37 slides | December 2017 |
| Shareholder Meeting (November 2017) | Shareholder meeting | 24 slides | Nov 30, 2017 |
| Shareholder Meeting (November 2017) | Shareholder meeting | 25 slides | Nov 30, 2017 |
| Shareholder Meeting (November 2016) | Shareholder meeting | 13 slides | Nov 14, 2016 |
| Shareholder Meeting (November 2015) | Shareholder meeting | 33 slides | Nov 18, 2015 |
| Investor Presentation (November 2015) | Investor deck | 31 slides | Nov 10, 2015 |
| Investor Presentation (September 2015) | Investor deck | 35 slides | Sep 7, 2015 |
| Investor Presentation (August 2015) | Investor deck | 36 slides | Aug 6, 2015 |
| Investor Presentation (July 2015) | Investor deck | 10 slides | Jul 27, 2015 |
| Investor Presentation (July 2015) | Investor deck | 35 slides | July 2015 |
| Corporate Update (June 2015) | Corporate update | 11 slides | Jun 16, 2015 |
| Investor Presentation (March 2015) | Investor deck | 32 slides | Mar 20, 2015 |
| Shareholder Meeting (November 2014) | Shareholder meeting | 24 slides | Nov 21, 2014 |
| Investor Presentation (June 2014) | Investor deck | 33 slides | Jun 6, 2014 |
| Investor Presentation (April 2014) | Investor deck | 30 slides | Apr 9, 2014 |
| Investor Presentation (February 2014) | Investor deck | 27 slides | Feb 26, 2014 |
| Shareholder Meeting (November 2013) | Shareholder meeting | 32 slides | Nov 22, 2013 |
| Investor Presentation (October 2013) | Investor deck | 38 slides | Oct 28, 2013 |
| Investor Presentation (September 2013) | Investor deck | 25 slides | September 2013 |
| AsiaBiotech Invest 2013 | Conference | 32 slides | Jun 3, 2013 |
| Investor Presentation (June 2013) | Investor deck | 31 slides | June 2013 |
| Investor Presentation (April 2013) | Investor deck | 18 slides | Apr 2, 2013 |
| Investor Presentation (February 2013) | Investor deck | 19 slides | Feb 25, 2013 |
| Investor Presentation (September 2012) | Investor deck | 27 slides | Sep 11, 2012 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Securities Announced: raise | Sep 29, 2026 | |
| Convertible director loans Announced: A$400,000 · A$0.05 a share Buyers: Prof Thian Chew (Up to $200,000 loan); Alan Yamashita (Up to $200,000 loan) Insiders: Loans provided by Executive Chair & CEO Prof Thian Chew and Non-Executive Director Alan Yamashita, up to $200,000 each Use of proceeds: Working capital requirements | Sep 29, 2026 | US$279,335 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 385.3K | 0 | 3.69M | 4.10M | 3.29M | 2.33M | 3.48M | 3.88M | 737.7K | 0 |
| Cost of revenue | 1.29M | 2.69M | 2.90M | 2.32M | 1.52M | 1.56M | 2.26M | 370.9K | 1.24M | |
| Gross profit | 385.3K | -1.29M | 1.00M | 1.21M | 969.1K | 810.5K | 1.92M | 1.63M | 366.8K | -1.24M |
| Research and development | 1.48M | 1.29M | 2.69M | 2.90M | 2.32M | 1.52M | 1.55M | 2.23M | 363.7K | 30.9K |
| Selling, general and administrative | 2.12M | 2.02M | 1.33M | 1.05M | 1.12M | 844.7K | 759.6K | 1.41M | 769.3K | 318.7K |
| Operating income | -3.94M | -5.29M | -5.68M | -1.65M | -2.32M | -1.57M | -1.03M | -2.52M | -960.5K | -2.09M |
| Depreciation and amortization | 1.72M | 4.81M | 816.0K | 683.1K | 422.4K | 277.9K | 277.9K | 309.6K | 1.33M | 1.24M |
| EBITDA | -2.22M | -471.8K | -4.86M | -965.4K | -1.90M | -1.29M | -748.6K | -2.21M | 364.7K | -840.4K |
| Interest expense | 346.8K | 694.8K | 240.0K | 53 | 0 | 0 | 0 | 117.9K | 144.4K | |
| Income before tax | -5.63M | -8.81M | -5.63M | -1.61M | -2.24M | -1.48M | -953.9K | -2.55M | -926.5K | -6.46M |
| Income tax | -3 | 3 | 193.9K | 3 | 3 | 137.7K | -163.3K | -4.26M | ||
| Net income | -5.63M | -8.81M | -5.63M | -1.61M | -2.24M | -1.48M | -953.9K | -2.55M | -926.5K | -2.20M |
| Earnings per share, basic | -0.06 | -0.12 | -0.09 | -0.03 | -0.04 | -0.00 | -0.00 | -0.00 | -0.02 | -0.14 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 592.3K | 850.4K | 783.5K | 4.08M | 8.47M | 1.04M | 618.8K | 771.3K | 2.89M | 917.5K |
| Short-term investments | 0 | |||||||||
| Receivables | 1.21M | 1.62M | 140.0K | 11.0K | 271.8K | 28.8K | 91.8K | 32.3K | ||
| Inventory | -1.21M | 1 | 0 | -91.8K | -32.3K | |||||
| Current assets | 697.4K | 933.2K | 2.08M | 5.76M | 8.65M | 1.08M | 916.9K | 942.2K | 3.06M | 1.01M |
| Property, plant and equipment | 58.5K | 479 | 1.02K | 3.89K | 4.82K | 0 | 2.64K | |||
| Total assets | 8.17M | 9.49M | 15.5M | 19.0M | 20.0M | 5.64M | 5.76M | 6.06M | 10.3M | 5.81M |
| Accounts payable | 1.16M | 542.8K | 720.9K | 399.8K | 221.3K | 448.9K | 105.7K | 308.1K | 567.8K | 117.4K |
| Current liabilities | 2.85M | 1.24M | 1.01M | 650.6K | 462.4K | 851.5K | 326.8K | 604.7K | 1.78M | 1.80M |
| Long-term debt | 0 | |||||||||
| Total debt | 1.55M | 20.3K | 3.74M | |||||||
| Total liabilities | 2.85M | 1.24M | 1.01M | 650.6K | 462.4K | 851.5K | 326.8K | 604.7K | 2.44M | 1.80M |
| Shareholders' equity | 5.32M | 8.25M | 14.4M | 18.4M | 19.6M | 4.79M | 5.43M | 5.46M | 7.91M | 4.01M |
| Shares outstanding | 90.0M | 72.0M | 64.2M | 64.2M | 61.2M | 5.53B | 5.50B | 5.50B | 38.1M | 15.9M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.37M | -2.97M | -2.40M | -1.81M | -1.11M | 418.0K | -152.5K | -2.11M | 707.1K | -247.1K |
| Capital spending | -4.11K | 0 | -900.0K | -2.58M | -7.25M | -7.25M | -75.8K | -6.05K | -6.05K | -6.05K |
| Free cash flow | -2.38M | -2.97M | -3.30M | -4.39M | -8.36M | 418.0K | -152.5K | -2.11M | 707.1K | -247.1K |
| Cash from investing | -68.8K | 0 | -900.0K | -2.58M | -7.25M | -7.25M | -7.25M | -13.6K | -13.6K | 53.9K |
| Cash from financing | 2.18M | 3.04M | 0 | 15.8M | 15.8M | 15.8M | 15.8M | 15.8M | 1.27M | 678.9K |
| Dividends paid | -982.0K | -663.5K | ||||||||
| Share buybacks | -36.1K | -170.3K | -842.0K | -842.0K | -842.0K | -286.1K | -15.4K | |||
| Change in cash | -258.1K | 66.8K | -3.30M | -4.39M | 7.44M | 418.0K | -152.5K | -2.12M | 1.97M | 480.1K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Invion Receives $0.5m R&D Tax Incentive Rebate | Nov 18, 2026 | Results | ASX |
| Change of Director's Interest Notice - Thian Chew | Nov 17, 2026 | Ownership change notice | ASX |
| Notification of cessation of securities - IVX | Nov 17, 2026 | Financing | ASX |
| IVX Director Appointment/Resignation & New Company Secretary | Nov 10, 2026 | Management or board change | ASX |
| Appendix 4C and Quarterly Activities Report - September 2026 | Oct 28, 2026 | Quarterly report | ASX |
| Notice of Annual General Meeting/Proxy Form | Oct 23, 2026 | Meeting notice | ASX |
| Proposed issue of securities - IVX | Oct 20, 2026 | Financing | ASX |
| Funding Agreements Cover Up to 85% of Clinical Trials Costs | Oct 20, 2026 | Financing | ASX |
| Funding Agreements Cover Up to 85% of Clinical Trials Costs | Oct 20, 2026 | Financing | ASX |
| Photosoft & Novel Immunotherapy Collab Partnership | Oct 19, 2026 | Other filings | ASX |
All 131 filings
Cap table
Built by 6ix from Invion Ltd.’s releases · as of Sep 29, 2026
- Common shares
- 110,553,134
- Fully diluted
- 110,553,134
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 110,553,134 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 110,553,134 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alan Yamashita | Non-Executive Director · Since at least Nov 12, 2026 |
| Louise White | Executive Manager · Since at least Nov 11, 2026 |
| Melanie Leydin | Non-Executive Director, Company Secretary & CFO · Since at least Nov 12, 2026 |
| Paul Field | Non-Executive Director · Since at least Nov 12, 2026 |
| Robert Ramsay | Chair of the Board · Since at least Nov 11, 2026 |
| Sebastian Marcuccio | Founder and Director at Advanced Molecular Technologies Pty Ltd (AMT) · Nov 4, 2026 – Nov 12, 2026 · Past |
| Thian Chew | Executive Chair and CEO · Since at least Nov 12, 2026 |
Log in to ask 6ix AI your own questions about Invion Ltd.